Alliance for Pandemic Preparedness

June 3, 2021

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Category:

Topic:

Keywords (Tags):

  • Preventive treatment with the monoclonal antibody bamlanivimab reduced the risk of COVID-19 among residents and staff of skilled nursing facilities (n=966) who were negative for SARS-CoV-2 infection and seronegative at baseline in a randomized trial (8.5% vs 15.2%, OR=0.43 95% CI 0.28-0.68). All 5 deaths occurred in residents randomized to receive placebo. Participants were enrolled from 74 skilled nursing and assisted living facilities in the US and received the treatment (bamlanivimab or a placebo infusion) within 7 days of a confirmed SARS-CoV-2 case at their facility. They were followed for 24 weeks with 8 additional tests for SARS-CoV-2 infection by RT-PCR.  Adverse events were balanced between the bamlanivimab and placebo groups.

Cohen et al. (June 3, 2021). Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. JAMA. https://doi.org/10.1001/jama.2021.8828